Key Takeaways
- • Private equity dealmakers, including ArchiMed, General Catalyst and THL Partners, are actively transacting in cardiometabolic care, according to a PitchBook-style deal roundup headlined "6 deals."
- • Investor interest is being driven by the GLP-1 drug boom and a broader shift of care toward outpatient settings.
- • The source article identifies six recent deals but the primary text available here does not itemize deal values, targets or terms.
Summary
Private equity firms are increasing their focus on cardiometabolic care, a therapeutic category covering conditions such as obesity, diabetes and cardiovascular disease, according to a deal-focused article covering six transactions. The article names ArchiMed, General Catalyst and THL Partners among the PE dealmakers active in the segment.
The article frames the activity against two structural trends: the growth of GLP-1 medications, which has expanded the population of patients managed for obesity and related metabolic conditions, and a continuing migration of care from hospitals to outpatient settings. Both trends have created demand for care delivery platforms and services that can manage chronic cardiometabolic patients at lower cost.
The primary source available for this summary is a paywalled excerpt that does not provide deal-level detail such as target names, transaction sizes or valuation multiples. Readers seeking the specific terms of the six transactions should consult the full article.
The article frames the activity against two structural trends: the growth of GLP-1 medications, which has expanded the population of patients managed for obesity and related metabolic conditions, and a continuing migration of care from hospitals to outpatient settings. Both trends have created demand for care delivery platforms and services that can manage chronic cardiometabolic patients at lower cost.
The primary source available for this summary is a paywalled excerpt that does not provide deal-level detail such as target names, transaction sizes or valuation multiples. Readers seeking the specific terms of the six transactions should consult the full article.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.